ES2530574T3 - Biomarcadores asociados a la nefropatía - Google Patents

Biomarcadores asociados a la nefropatía Download PDF

Info

Publication number
ES2530574T3
ES2530574T3 ES10735453T ES10735453T ES2530574T3 ES 2530574 T3 ES2530574 T3 ES 2530574T3 ES 10735453 T ES10735453 T ES 10735453T ES 10735453 T ES10735453 T ES 10735453T ES 2530574 T3 ES2530574 T3 ES 2530574T3
Authority
ES
Spain
Prior art keywords
nephropathy
combination
biomarkers
biomarker
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10735453T
Other languages
English (en)
Inventor
Tzu-Ling Tseng
Ching-Fang Lu
Wei-Ya Lin
Tsai-Wei Hsu
Mary Ya-Ping Yeh
Yi-Ting Chen
Chwei-Shiun Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industrial Technology Research Institute ITRI
Original Assignee
Industrial Technology Research Institute ITRI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industrial Technology Research Institute ITRI filed Critical Industrial Technology Research Institute ITRI
Application granted granted Critical
Publication of ES2530574T3 publication Critical patent/ES2530574T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

Un método de diagnóstico de la nefropatía en un sujeto, que comprende: obtener una muestra de orina de un sujeto que se sospecha que tiene nefropatía, determinar en la muestra de orina un nivel de un biomarcador o de una combinación de biomarcadores seleccionado del grupo que consiste en: (i) receptor-2 similar a Ig asociado a leucocitos o uno de sus fragmentos, y (ii) una combinación del receptor-2 similar a Ig asociado a leucocitos o uno de sus fragmentos y de la alfa- 1-glicoproteína ácida o uno de sus fragmentos, en donde el fragmento de receptor-2 similar a Ig asociado a leucocitos es DFLELLVKGTVPGTEASGFDAP (SEQ ID NO:1) y el fragmento de alfa-1-glicoproteína ácida es GQEHFAHLLILRDTKTYMLAFDVNDEKNWGLS (SEQ ID NO:2); y evaluar si el sujeto tiene nefropatía basándose en el nivel del biomarcador o de la combinación de biomarcadores, en donde un aumento en el nivel del biomarcador o de la combinación de biomarcadores, en comparación con un punto de referencia que representa el nivel del mismo biomarcador o de la combinación de biomarcadores en un sujeto sin nefropatía, indica que el sujeto tiene nefropatía, en donde el punto de referencia es el punto medio entre el nivel medio del biomarcador o de la combinación de biomarcadores en un grupo de pacientes con nefropatía y el de un grupo de sujetos sin nefropatía.
ES10735453T 2009-01-28 2010-01-27 Biomarcadores asociados a la nefropatía Active ES2530574T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14778509P 2009-01-28 2009-01-28
PCT/CA2010/000096 WO2010085878A1 (en) 2009-01-28 2010-01-27 Biomarkers associated with nephropathy

Publications (1)

Publication Number Publication Date
ES2530574T3 true ES2530574T3 (es) 2015-03-03

Family

ID=42395075

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10735453T Active ES2530574T3 (es) 2009-01-28 2010-01-27 Biomarcadores asociados a la nefropatía

Country Status (12)

Country Link
US (5) US20100209948A1 (es)
EP (1) EP2391653B8 (es)
JP (1) JP5524241B2 (es)
CN (1) CN102300875B (es)
BR (1) BRPI1007483B1 (es)
CA (1) CA2748852C (es)
DK (1) DK2391653T3 (es)
ES (1) ES2530574T3 (es)
MX (1) MX2011007810A (es)
PT (1) PT2391653E (es)
TW (1) TWI397687B (es)
WO (1) WO2010085878A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1007443B8 (pt) * 2009-01-28 2021-07-27 Bio Preventive Medicine Corp método para diagnosticar nefropatia diabética em um indivíduo, método para avaliar a eficácia de um tratamento para nefropatia diabética em um indivíduo, método para determinação do estágio da nefropatia diabética em um indivíduo, método para monitoramento do progresso da nefropatia diabética em um indivíduo, e método para avaliar a eficácia de um tratamento para nefropatia diabética em um indivíduo
KR101732706B1 (ko) * 2015-06-05 2017-05-04 압타바이오 주식회사 신증 진단용 마커로서의 sh3yl1의 용도
PL3469372T3 (pl) * 2016-06-10 2023-12-04 Warszawski Uniwersytet Medyczny Sposoby diagnozowania i monitorowania z wykorzystaniem białek moczu jako markerów nefropatii IgA
US20210364529A1 (en) * 2019-01-17 2021-11-25 National University Corporation Okayama University Method and kit for determining possibility of onset of iga nephropathy

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4640909A (en) * 1985-05-07 1987-02-03 J. T. Baker Chemical Company Bonded phase of silica and carboalkoxyalkyl silanes for solid phase extraction
SI0907735T2 (sl) * 1996-05-24 2010-01-29 Biogen Idec Inc Modulatorji tkivne regeneracije
DE69739751D1 (de) * 1996-12-06 2010-03-18 Schering Corp Isolierte gene aus säuger monozyten und betreffende reagentien
US6140076A (en) * 1996-12-06 2000-10-31 Schering Corporation Ig superfamily `dlair` receptors expressed in monocytes
MXPA01006404A (es) * 1998-12-21 2003-06-06 Univ Monash Deteccion y tratamiento de enfermedad renal.
US20040029175A1 (en) * 1998-12-21 2004-02-12 Comper Wayne D. Method for kidney disease detection
AUPP784398A0 (en) * 1998-12-21 1999-01-21 Monash University Kidney disease detection and treatment
US6682917B1 (en) * 1999-06-28 2004-01-27 Takeda Chemical Industries, Ltd Protein having a ribonucleotide Reductase activity and a DNA thereof
ES2312780T3 (es) * 2002-05-13 2009-03-01 Arexis Ab Afecciones autoinmunes y deficiencias de oxidasa nadph.
GB0215509D0 (en) * 2002-07-04 2002-08-14 Novartis Ag Marker genes
EP1616184B2 (en) * 2003-03-27 2018-05-30 Children's Hospital Medical Center A method and kit for detecting the early onset of renal tubular cell injury
BRPI0519096A2 (pt) * 2004-12-15 2008-12-23 Beth Israel Hospital Ácidos nuclÉicos e polipeptÍdeos éteis para o diagnàstico e tratamento de complicaÇÕes na gravidez
US20060257481A1 (en) * 2005-04-21 2006-11-16 Decode Genetics Ehf. Sustained release formulation and dosing schedule of leukotriene synthesis inhibitor for human therapy
EP2004850A2 (en) * 2006-03-08 2008-12-24 Universitair Medisch Centrum Utrecht Interfering in activation of an immune cell by influencing interaction of lair and collagen.
US7662578B2 (en) * 2006-04-21 2010-02-16 Children's Hospital Medical Center Method and kit for the early detection of impaired renal status
JP5244103B2 (ja) * 2006-08-09 2013-07-24 ホームステッド クリニカル コーポレイション 器官特異的蛋白質およびその使用方法
WO2008021431A2 (en) * 2006-08-14 2008-02-21 Xdx, Inc. Methods and compositions for diagnosing and monitoring the status of transplant rejection and immune disorders
EP2089539B1 (en) * 2006-10-13 2011-12-07 Metabolon, Inc. Biomarkers related to metabolic age and methods using the same
US20080187944A1 (en) * 2007-01-31 2008-08-07 Appa Rao Allam Butyrylcholinesterase as a marker of low-grade systemic inflammation
CN101680903A (zh) * 2007-03-21 2010-03-24 比奥波托诊断股份公司 肾损伤的诊断试验
US9000134B2 (en) * 2007-05-11 2015-04-07 Wallace B. Haigh Reagent and kit for early diagnosis of kidney disease
BRPI1007443B8 (pt) * 2009-01-28 2021-07-27 Bio Preventive Medicine Corp método para diagnosticar nefropatia diabética em um indivíduo, método para avaliar a eficácia de um tratamento para nefropatia diabética em um indivíduo, método para determinação do estágio da nefropatia diabética em um indivíduo, método para monitoramento do progresso da nefropatia diabética em um indivíduo, e método para avaliar a eficácia de um tratamento para nefropatia diabética em um indivíduo

Also Published As

Publication number Publication date
PT2391653E (pt) 2015-02-13
US20110081667A1 (en) 2011-04-07
US20100209948A1 (en) 2010-08-19
US8470547B2 (en) 2013-06-25
US20110086372A1 (en) 2011-04-14
EP2391653B1 (en) 2014-12-31
BRPI1007483A2 (pt) 2016-02-16
EP2391653A4 (en) 2012-06-27
EP2391653A1 (en) 2011-12-07
TWI397687B (zh) 2013-06-01
US20130266976A1 (en) 2013-10-10
CN102300875B (zh) 2014-07-16
BRPI1007483B1 (pt) 2021-11-30
CA2748852C (en) 2019-05-28
US9442120B2 (en) 2016-09-13
JP5524241B2 (ja) 2014-06-18
CN102300875A (zh) 2011-12-28
WO2010085878A1 (en) 2010-08-05
TW201033615A (en) 2010-09-16
CA2748852A1 (en) 2010-08-05
US20110081668A1 (en) 2011-04-07
MX2011007810A (es) 2011-09-30
JP2012516430A (ja) 2012-07-19
EP2391653B8 (en) 2015-09-30
DK2391653T3 (en) 2015-02-09

Similar Documents

Publication Publication Date Title
GB2467704A (en) Methods of monitoring conditions by sequence analysis
MX2013001042A (es) Biomarcadores de cancer pancreatico y usos de los mismos.
PH12012500850A1 (en) Methods for diagnosing irritable bowel syndrome
CR20110567A (es) Dispositivos para diagnostico y metodos relacionados
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
MX368394B (es) Receptor alfa de folato como marcador de diagnostico y pronostico para canceres que expresan receptor alfa de folato.
MX355020B (es) Biomarcadores de cancer de pulmon y usos de los mismos.
WO2016198833A3 (en) Methods for analysing a urine sample
EP2302079A3 (en) Systemic lupus erythematosus diagnostic assay
EA201290629A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
NZ610356A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2829881A3 (en) Diagnostic for colorectal cancer
WO2011021041A3 (en) Survival prognostic assay
EP1989551A4 (en) METHOD OF DETECTING OR DIAGNOSING NEURODEGENERATIVE DISEASE OR DISEASE
MY162697A (en) Methods, devices and kits for detecting or monitoring acute kidney injury
NZ624614A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ594772A (en) Diagnosis and prognosis of renal injury and renal failure using vitamin k dependent protein c
CO6311041A2 (es) Un metodo para determinar y monitorear un cancer ginecologico que comprende la determinacion de niveles de biomarcadores en una muestra biologica
EA201790696A1 (ru) Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности
NZ599773A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
RU2019104870A (ru) Комбинированный тест на наличие колоректального рака
ES2530574T3 (es) Biomarcadores asociados a la nefropatía
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
GEAP202515717A (en) Salivary biomarkers of brain injury